← All trials
NCT04405271
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2020
- Primary completion
- Nov 15, 2020
- Completion date
- Nov 15, 2020
- First posted
- May 28, 2020
- Last posted
- May 28, 2020
- Enrollment
- 1378
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hospital Italiano de Buenos AiresLead sponsor
- Hospital Italiano de Buenos AiresReponsible party - principal investigator
- Hospital Italiano de Buenos AiresStudy chair
- Hospital Alende (Mar del Plata)Overall official - principal investigator
- Hospital AustralOverall official - principal investigator
- Hospital Bernardo HoussayOverall official - principal investigator
- Hospital Italiano de La PlataOverall official - principal investigator
- Hospital Padilla (Tucumán)Overall official - principal investigator
- Sanatorio Allende (Córdoba)Overall official - principal investigator
- Sanatorio BritanicoOverall official - principal investigator
- Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.